Title:
COMBINATION THERAPY USE OF LACTOBACILLUS FERMENTUM STRAIN AND NATURAL KILLER CELLS FOR PREVENTING AND TREATING METABOLIC DISEASES
Document Type and Number:
WIPO Patent Application WO/2022/265430
Kind Code:
A1
Abstract:
The present invention relates to: a composition comprising a Lactobacillus fermentum strain, preferably a Lactobacillus fermentum GB-102 strain deposited under accession number KCTC 14105BP, and natural killer cells; and a combination therapy use of the strain and natural killer cells for inhibiting weight gain or preventing and/or treating metabolic diseases. The composition and the combination therapy of the present invention exhibit a remarkable inhibitory effect on weight gain. Therefore, the composition and the combination therapy of the present invention can be easily used in regulating the weight of a subject, and thus can be effectively used in the cosmetic, livestock and medical fields and the like and, in particular, can be effectively used in the fields of pharmaceutical compositions, food additives, health functional foods, therapeutic agents and the like for alleviating, preventing and treating metabolic diseases including obesity.
More Like This:
Inventors:
YANG BO-GIE (KR)
HONG CHUN-PYO (KR)
KIM CHEA HA (KR)
LEE DAJEONG (KR)
KIM HYE RI (KR)
JANG MYUNG HO (KR)
HONG CHUN-PYO (KR)
KIM CHEA HA (KR)
LEE DAJEONG (KR)
KIM HYE RI (KR)
JANG MYUNG HO (KR)
Application Number:
PCT/KR2022/008553
Publication Date:
December 22, 2022
Filing Date:
June 16, 2022
Export Citation:
Assignee:
GI CELL INC (KR)
GI BIOME (KR)
GI BIOME (KR)
International Classes:
A61K35/747; A23L33/10; A23L33/105; A23L33/135; A61K35/17; A61K36/068; A61K36/8945; A61P3/04
Domestic Patent References:
| WO2021061789A1 | 2021-04-01 | |||
| WO2019157585A1 | 2019-08-22 |
Foreign References:
| KR101862051B1 | 2018-05-29 | |||
| KR20200103219A | 2020-09-02 | |||
| KR101985792B1 | 2019-06-05 | |||
| KR101494279B1 | 2015-04-29 | |||
| KR100996577B1 | 2010-11-24 | |||
| KR101394348B1 | 2014-05-13 | |||
| KR20210086537A | 2021-07-08 |
Other References:
J CLIN INVEST, vol. 106, 2000, pages 171 - 76
DIABETES, vol. 37, 1988, pages 1595 - 607
NAT REV GASTROENTEROL HEPATOL, vol. 11, 2014, pages 506 - 514
PROC. NUTR. SOC., vol. 63, pages 375 - 380
J. LIPID RES., vol. 50, pages S74 - S79
DIABETES, vol. 60, pages 2588 - 2597
L. LACHMAN ET AL., THE THEORY AND PRACTICE OF INDUSTRIAL PHARMACY, 1986, pages 365 - 373
H. SUCKER ET AL., PHARMAZEUTISCHE TECHNOLOGIE, THIEME, 1991, pages 355 - 359
"Hagers Handbuch der pharmazeutischen Praxis", vol. 7, 1971, SPRINGER VERLAG, pages: 739 - 742,766-778
"Remington's Pharmaceutical Sciences", 1970, MACK PUBL., CO., pages: 1689 - 1691
DIABETES, vol. 37, 1988, pages 1595 - 607
NAT REV GASTROENTEROL HEPATOL, vol. 11, 2014, pages 506 - 514
PROC. NUTR. SOC., vol. 63, pages 375 - 380
J. LIPID RES., vol. 50, pages S74 - S79
DIABETES, vol. 60, pages 2588 - 2597
L. LACHMAN ET AL., THE THEORY AND PRACTICE OF INDUSTRIAL PHARMACY, 1986, pages 365 - 373
H. SUCKER ET AL., PHARMAZEUTISCHE TECHNOLOGIE, THIEME, 1991, pages 355 - 359
"Hagers Handbuch der pharmazeutischen Praxis", vol. 7, 1971, SPRINGER VERLAG, pages: 739 - 742,766-778
"Remington's Pharmaceutical Sciences", 1970, MACK PUBL., CO., pages: 1689 - 1691
Attorney, Agent or Firm:
LEE, Cheo Young et al. (KR)
Download PDF: